Citations

Clear

32 citation(s) found for "Smith, Andrew J P".

Effectiveness of Infliximab for Refractory Non-ischemic Cerebral Enhancing Foreign-body Granulomatous Lesions Following Endovascular Therapy (P1-1.003)
Taha, Farris, Tagg, Nathan, Smith, Andrew, Flanagan, Eoin , Brown, Robert, Pittock, Sean, Perez-Giraldo, Gina, McKeon, Andrew, Aboseif, Albert , Taha, Farris , Tagg, Nathan T. , Flanagan, Eoin P. , Pittock, Sean J. , Perez-Giraldo, Gina , McKeon, Andrew

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215791 Get It

Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy
Aboseif, Albert , Taha, Farris , Tagg, Nathan T. , Smith, Andrew D. , Brown, Robert D. , Pittock, Sean J. , Perez-Giraldo, Gina , McKeon, Andrew , Pittock, S J , Flanagan, E P , Brown, Robert D , Perez Giraldo, Gina S , McKeon, Andrew , Aboseif, Albert , Flanagan, Eoin P.

Mayo Clinic

Neurology | October 29, 2025 | Volume: 105 | Issue: 10 | Pages: No page available

10.1212/wnl.0000000000214345 | PMID 41160790 Get It

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Collinge, Brett , Hilton, Laura K. , Wong, Jasper , Alduaij, Waleed , Ben‐Neriah, Susana , Slack, Graham W. , Farinha, Pedro , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ott, G., Rosenwald, Andreas , Amador, Catalina , Greiner, Timothy C. , Ondrejka, Sarah L. , Weisenburger, Dennis D. , Beiske, Klaus , Fu, Kai , Iqbal, Javeed , Wright, George, Staudt, Louis M. , Boyle, Merrill , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Ondrejka, Sarah , Jaffe, Elaine S , Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Steidl, Christian , Feldman, Andrew L , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Alduaij, Waleed , Farinha, Pedro , Hilton, Laura K , Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Chan, Wing C., Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J. , Mungall, Andrew J. , Steidl, Christian , Feldman, Andrew L. , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood Advances | July 17, 2025 | Volume: 9 | Issue: 21 | Pages: 5409-5422

10.1182/bloodadvances.2025016651 | PMID 40674706 Get It

Abstract Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.
Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial
Roke, Rachel , Lillie, Erin , Daneman, Nick , Mason, Stephanie, Jiang, Yidi , Shiroky, Jonah , Puran, Sudarshani, Smith, David E. , Khalil, Jad Abou, Kayssi, Ahmed , Pinchuk, Brian, Apte, Sameer , Lamb, Tyler , Ma, Grace , Vogt, Kelly, Leslie, Kenneth , Mutabdzic, Dorotea, Gómez, David , Ladha, Karim S. , Bennett, Sean, Ullah, Shahnoor M, Holland, Jessica, Smith, Andrew J., Calderone, Michael, Herriott, Judith, Voltan, Ed, Sloan, B., Mazer, C. David , Kennedy, Erin, Aarts, Mary-Anne, Karanicolas, Paul J. , Kayssi, Ahmed , Apte, Sameer S , Lamb, Tyler , Delisle, Megan , Muaddi, Hala , Fergusson, Dean A , Marshall, John C. , Karanicolas, Paul Jack , Tomlinson, George , Serrano, Pablo E , Vogt, Kelly, Tsang, Melanie E. , Ullah, Shahnoor M, Nathens, Avery B.

Mayo Clinic

BMJ Open | July 17, 2025 | Volume: 15 | Issue: 7 | Pages: e104375

10.1136/bmjopen-2025-104375 | PMID 40675632 Get It

Introduction In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).
Developing a Decision Support Tool to Guide Shared Decision‐Making in Bipolar Depression Treatment: Results From a Collaboration Between Clinicians and People With Lived Experience
Fuentes‐Salgado, Manuel, Gardea‐Resendez, Manuel , Ercis, Mete , Kremin, Ashley, Joyce, Jeremiah B. , Park, Jin Hong , Keeth, Nicola , Moore, Katherine M. , Betcher, Hannah K. , Yang, Padao, Williams, Mark D. , Michael, P., Frye, Mark A. , Lam, Angie, Ercis, Mete , Moore, Katherine, Betcher, Hannah, Savitz, Samuel T. , Frye, Mark , Joyce, Jeremiah , Gardea-Resendez, Manuel , Smith, Andrew, Lam, Angie, Allen, Kimberly, Kremin, Ashley, Leung, Jonathan G. , Özerdem, Ayşegül , Montori, Víctor M.

Mayo Clinic

Bipolar Disorders | June 10, 2025 | Volume: 27 | Issue: 5 | Pages: 358-364

10.1111/bdi.70037 | PMID 40491157 Get It

ABSTRACTObjectiveTo build consensus from different stakeholders on the content and digital interactivity of a shared decision making (SDM) tool to guide patient‐clinician collaborative conversations about treatment for bipolar depression.Patients and MethodsThis study was conducted between September 2022 and September 2023. In the first phase, we conducted a narrative review on pharmacological, neuromodulatory, and psychotherapeutic treatments available for bipolar depression. For each option, we assessed treatment effectiveness, side effects, need for clinical monitoring, clinical considerations, and cost. In the second phase, committees comprised of mental health clinicians and people with lived experience with bipolar disorder from a national mood disorders advocacy group identified key features and content to be included in the SDM tool. A thematic analysis of these data then contributed to populate the SDM tool.ResultsTwenty‐one evidence‐based treatment options identified from the narrative review were presented to the four convened committees (clinical, lived experience, peer council, and integrated steering committees) in five meetings. After discussions and thematic analysis, 12 outcomes of interest for each of the therapeutic interventions were delineated for inclusion in a web‐based SDM tool. A detailed description of the development process and SDM tool is provided.ConclusionThis is the first partnership between clinicians and persons with bipolar disorder lived experience charged with the development of a patient‐centered SDM tool to integrate clinical evidence with real‐world clinical practice and patient preferences for use during clinical encounters. Human‐centered design and testing in real clinical encounters will now contribute to refining the instrument and readying it for rigorous evaluation and implementation in practice.
Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory
Berglund, Anders , Puskas, John , Yoder, Sean , Smith, Andrew T. , Marchion, Douglas C. , Qin, Dahui , Mulé, James J. , Torres–Roca, Javier F. , Berglund, Anders E , Yoder, Sean J , Eschrich, Steven A

Mayo Clinic

Cancer Research Communications | February 11, 2025 | Volume: 5 | Issue: 3 | Pages: 389-397

10.1158/2767-9764.crc-24-0534 | PMID 39932296 Get It

Abstract The radiation sensitivity index (RSI) and 12-chemokine gene expression signature (12CK GES) are two gene expression signatures (GES) that were previously developed to predict tumor radiation sensitivity or identify the presence of tertiary lymphoid structures in tumors, respectively. To advance the use of these GESs into clinical trial evaluation, their assays must be assessed within the context of the Clinical Laboratory Improvement Amendments (CLIA) process. Using HG-U133Plus2.0 arrays, we first established CLIA laboratory proficiency. Then the accuracy (limit of detection and macrodissection impact), precision (variability by time and operator), sample type (surgery vs. biopsy), and concordance with a reference laboratory were evaluated. RSI and 12CK GES were reproducible (RSI: 0.01 mean difference, 12CK GES: 0.17 mean difference) and precise with respect to time and operator. Taken together, the reproducibility analysis of the scores indicated a median RSI difference of 0.06 (6.47% of range) across samples and a median 12CK GES difference of 0.92 (12.29% of range). Experiments indicated that the lower limit of input RNA is 5 ng. Reproducibility with a second CLIA laboratory demonstrated reliability with the median RSI score difference of 0.065 (6% of full range) and 12CK GES difference of 0.93 (12% of observed range). Overall, under CLIA, RSI and 12CK GES were demonstrated by the Moffitt Cancer Center Advanced Diagnostic Laboratory to be reproducible GESs for clinical usage. Significance: The RSI and 12CK GES are two GESs that predict tumor radiation sensitivity or the presence of tertiary lymphoid structures in tumors, respectively. These GESs were assessed within the CLIA process for future clinical use. We established proficiency, reproducibility, and reliability characteristics for both signatures in a controlled setting, indicating these GESs are suitable for validation within future clinical trials.
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Hilton, Laura K. , Collinge, Brett , Alduaij, Waleed , Shaalan, Haya, Weng, Andrew P. , Cruz, Manuela Martins , Slack, Graham W. , Farinha, Pedro , Miyata‐Takata, Tomoko , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus, Fu, Kai , Delabie, Jan , Pittaluga, Stafania, Iqbal, Javeed , Wright, George, Staudt, Louis M. , Wright, George W. , Alduaij, Waleed , Weng, Andrew P , Farinha, Pedro , Boyle, Merrill , Cook, James R , Ondrejka, Sarah , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Jaffe, Elaine S , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Feldman, Andrew L , Steidl, Christian , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Wright, George , Hilton, Laura K , Ben‐Neriah, Susana , Cruz, Manuela, Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Sehn, Laurie H. , Savage, Kerry J. , Mungall, Andrew J. , Feldman, Andrew L. , Steidl, Christian , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood | May 3, 2024 | Volume: 144 | Issue: 5 | Pages: 525-540

10.1182/blood.2024024251 | PMID 38701426 Get It

Abstract Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
Treatment of Anti-DPPX-Encephalitis Refractory to Corticosteroids, Plasma Exchange and Rituximab (P2.163)
Samkoff, Lawrence, Smith, Andrew Paul , Goodman, Andrew D. , McKeon, Andrew

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p2.163 Get It

Inclusion of Comorbidities and Prognosis in U.S. States' Triage Plans During COVID-19
Ennis, Jackson S, Nguyen, N.V. , Kramer, D.B., Smith, Andrew , Sulmasy, Dan, Tilburt, Jon C. , DeMartino, Erin S. , Ennis, Jackson S. , Riggan, Kirsten A. , Wolf, Susan M.

Mayo Clinic

D93. CLINICAL AND TRANSLATIONAL STUDIES OF COVID-19 CRITICAL ILLNESS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6554-A6554

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6554 Get It